News for Protagonist Therapeutics, Inc. (PTGX)

U.S. stocks were lower, with the Nasdaq Composite falling around 650 points on Monday. Shares of Redfin Corporation RDFN rose sharply during Monday's session a...

PR NewswireSPRING HOUSE, Pa., March 10, 2025 Topline results also show investigational targeted oral peptide icotrokinra achieved clinical remission rates

Protagonist Therapeutics Inc (PTGX) has released new data from its Phase 3 clinical program for icotrokinra, an investigational oral peptide targeting the IL-23

Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICO

Protagonist Therapeutics, Inc. (PTGX) and Takeda Pharmaceutical Company Limited (TAK) Monday announced positive topline results from the Phase 3 VERIFY study of rusfertide in Patients with Polycythemia Vera, a type of blood cancer.

Protagonist Therapeutics, Inc. (”œProtagonist”) ([url="]NASDAQ:PTGX[/url]) and Takeda ([url="]TSE:4502/NYSE:TAK[/url]) today announced positive topline resu

Protagonist Therapeutics Inc (PTGX) has released its financial results for the fourth quarter and full year ending December 31, 2024, along with a corporate upd

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 3,200% and 202.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

On December 31, 2024, ADAR1 Capital Management, LLC (Trades, Portfolio) executed a notable transaction involving iBio Inc. The firm increased its stake in the b

Overview of the Recent Transaction On December 31, 2024, ADAR1 Capital Management, LLC (Trades, Portfolio) made a strategic move by acquiring 6,994,246 shares o

The company had $583.3 million in cash as of September 30th of 2024; Enough cash to fund its operations until the end of 2027. Explore more details here.

Summary Protagonist Therapeutics Inc (PTGX), a late-stage biopharmaceutical company, announced on January 6, 2025, the issuance of inducement awards to Dr. Newm

NEWARK, CALIFORNIA / ACCESSWIRE / January 6, 2025 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on January 2, 2025, it issued inducement aw

Insider Activity Roundup: Wednesday's Top Buys and Sells Revealed

U.S. stocks were mixed, with the Dow Jones index gaining more than 150 points on Friday. Shares of Natural Grocers by Vitamin Cottage, Inc. NGVC rose sharply d...

NEWARK, CA / ACCESSWIRE / November 22, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., Presi

Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF)IND enabling

PR NewswireSPRING HOUSE, Pa., Nov. 18, 2024 Icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide that selectively blocks the IL-2

Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.